Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.51 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | PRKACG | P22612 | 2/20 | 0.51 |
| ▸ | PRKACB | P22694 | 2/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 10/20 | 0.48 |
| ▸ | AKT2 | P31751 | 10/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494310 | 0.85 | AKT1 (0.60) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3490901 | 0.85 | KIT (0.59) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL13369034 | 0.83 | LIMK2 (0.39) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3491258 | 0.83 | KIT (0.52) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3493470 | 0.82 | AKT2 (0.49) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3492843 | 0.81 | AKT2 (0.49) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3494018 | 0.80 | KMT2A (0.43) | — | |
| SCHEMBL3491514 | 0.78 | KMT2A (0.44) | — | |
| SCHEMBL3492620 | 0.78 | AKT2 (0.49) | ROCK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL3492127 | 0.78 | AKT2 (0.53) | ROCK2KITAKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | ROCK2 83/4885PRKACA 595/4885PRKACG 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.